- Home
- MESO vs WABC Comparison
MESO vs WABC Comparison
Compare MESO & WABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- WABC
- Stock Information
- Founded
- MESO 2004
- WABC 1972
- Country
- MESO Australia
- WABC United States
- Employees
- MESO 81
- WABC N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- WABC Major Banks
- Sector
- MESO Health Care
- WABC Finance
- Exchange
- MESO Nasdaq
- WABC Nasdaq
- Market Cap
- MESO 2.0B
- WABC 1.2B
- IPO Year
- MESO N/A
- WABC N/A
- Fundamental
- Price
- MESO $15.60
- WABC $47.30
- Analyst Decision
- MESO Buy
- WABC Hold
- Analyst Count
- MESO 2
- WABC 2
- Target Price
- MESO $24.00
- WABC $52.00
- AVG Volume (30 Days)
- MESO 213.4K
- WABC 147.7K
- Earning Date
- MESO 08-28-2025
- WABC 10-16-2025
- Dividend Yield
- MESO N/A
- WABC 3.90%
- EPS Growth
- MESO N/A
- WABC N/A
- EPS
- MESO N/A
- WABC 4.59
- Revenue
- MESO $17,198,000.00
- WABC $264,660,000.00
- Revenue This Year
- MESO $288.50
- WABC N/A
- Revenue Next Year
- MESO $167.17
- WABC N/A
- P/E Ratio
- MESO N/A
- WABC $10.27
- Revenue Growth
- MESO 191.39
- WABC N/A
- 52 Week Low
- MESO $8.34
- WABC $42.00
- 52 Week High
- MESO $22.00
- WABC $59.97
- Technical
- Relative Strength Index (RSI)
- MESO 39.64
- WABC 45.71
- Support Level
- MESO $16.10
- WABC $47.45
- Resistance Level
- MESO $16.91
- WABC $48.76
- Average True Range (ATR)
- MESO 0.50
- WABC 1.03
- MACD
- MESO -0.27
- WABC 0.07
- Stochastic Oscillator
- MESO 0.60
- WABC 60.05
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About WABC Westamerica Bancorporation
Westamerica Bancorp is based in San Rafael, California. Westamerica Bancorporation runs a regional community bank and has approximately $7.5 billion in assets. The banks' net revenue is generated by net interest income. Deposit service charges make up the noninterest income sources. The bank focuses mostly on commercial clients, such as smaller businesses. Its footprint encompasses central and northern California, extending north of San Francisco to Mendocino and Lake counties, south to Kern County in central California and all the way east to Nevada County.